Tags

Type your tag names separated by a space and hit enter

Rapid hip bone loss in active Crohn's disease patients receiving short-term corticosteroid therapy.
Aliment Pharmacol Ther. 2004 Nov 01; 20(9):951-7.AP

Abstract

BACKGROUND

Uncertainty over whether corticosteroids cause bone loss in patients with Crohn's disease may reflect their short, intermittent use.

AIM

We investigated whether a 2-month course of prednisolone is associated with detectable bone loss.

METHODS

Fifteen patients with active Crohn's disease and 19 controls with inactive Crohn's disease were recruited. Bone mineral density of the lumbar spine and hip was measured at baseline and 2 and 8 months.

RESULTS

At 2 months, significant bone loss was found in patients with active disease (femoral neck -2.7%, P < 0.002; Ward's triangle -3.9%, P < 0.01). Although bone mineral density was still lower at 8 months, these differences were no longer significant (-1.3% and -3.4%, femoral neck and Ward's triangle, respectively). No significant change in hip bone mineral density was observed in controls. Previous corticosteroid use was not significantly associated with baseline bone mineral density, although significant independent associations were observed between weight, site of disease and lumbar spine bone mineral density, and between dietary calcium deficiency and femoral neck and Ward's triangle bone mineral density.

CONCLUSION

Significant bone loss at the hip can be detected in patients receiving corticosteroid treatment for 2 months for active Crohn's disease ; however, it remains unclear whether this is because of disease activity or its treatment. This rapid bone loss may represent a risk factor for fracture and justify bone protective therapy.

Authors+Show Affiliations

Department of Clinical Science at South Bristol, University of Bristol, Bristol, UK.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15521842

Citation

Tobias, J H., et al. "Rapid Hip Bone Loss in Active Crohn's Disease Patients Receiving Short-term Corticosteroid Therapy." Alimentary Pharmacology & Therapeutics, vol. 20, no. 9, 2004, pp. 951-7.
Tobias JH, Sasi MR, Greenwood R, et al. Rapid hip bone loss in active Crohn's disease patients receiving short-term corticosteroid therapy. Aliment Pharmacol Ther. 2004;20(9):951-7.
Tobias, J. H., Sasi, M. R., Greenwood, R., & Probert, C. S. (2004). Rapid hip bone loss in active Crohn's disease patients receiving short-term corticosteroid therapy. Alimentary Pharmacology & Therapeutics, 20(9), 951-7.
Tobias JH, et al. Rapid Hip Bone Loss in Active Crohn's Disease Patients Receiving Short-term Corticosteroid Therapy. Aliment Pharmacol Ther. 2004 Nov 1;20(9):951-7. PubMed PMID: 15521842.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rapid hip bone loss in active Crohn's disease patients receiving short-term corticosteroid therapy. AU - Tobias,J H, AU - Sasi,M R, AU - Greenwood,R, AU - Probert,C S J, PY - 2004/11/4/pubmed PY - 2005/2/18/medline PY - 2004/11/4/entrez SP - 951 EP - 7 JF - Alimentary pharmacology & therapeutics JO - Aliment Pharmacol Ther VL - 20 IS - 9 N2 - BACKGROUND: Uncertainty over whether corticosteroids cause bone loss in patients with Crohn's disease may reflect their short, intermittent use. AIM: We investigated whether a 2-month course of prednisolone is associated with detectable bone loss. METHODS: Fifteen patients with active Crohn's disease and 19 controls with inactive Crohn's disease were recruited. Bone mineral density of the lumbar spine and hip was measured at baseline and 2 and 8 months. RESULTS: At 2 months, significant bone loss was found in patients with active disease (femoral neck -2.7%, P < 0.002; Ward's triangle -3.9%, P < 0.01). Although bone mineral density was still lower at 8 months, these differences were no longer significant (-1.3% and -3.4%, femoral neck and Ward's triangle, respectively). No significant change in hip bone mineral density was observed in controls. Previous corticosteroid use was not significantly associated with baseline bone mineral density, although significant independent associations were observed between weight, site of disease and lumbar spine bone mineral density, and between dietary calcium deficiency and femoral neck and Ward's triangle bone mineral density. CONCLUSION: Significant bone loss at the hip can be detected in patients receiving corticosteroid treatment for 2 months for active Crohn's disease ; however, it remains unclear whether this is because of disease activity or its treatment. This rapid bone loss may represent a risk factor for fracture and justify bone protective therapy. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/15521842/Rapid_hip_bone_loss_in_active_Crohn's_disease_patients_receiving_short_term_corticosteroid_therapy_ L2 - https://doi.org/10.1111/j.1365-2036.2004.02207.x DB - PRIME DP - Unbound Medicine ER -